KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Total Current Liabilities data on record, last reported at $4.4 billion in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 10.75% year-over-year to $4.4 billion; the TTM value through Dec 2025 reached $4.4 billion, up 10.75%, while the annual FY2025 figure was $4.4 billion, 10.75% up from the prior year.
  • Total Current Liabilities reached $4.4 billion in Q4 2025 per REGN's latest filing, down from $4.4 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $4.4 billion in Q3 2025 and bottomed at $2.9 billion in Q3 2022.
  • Average Total Current Liabilities over 5 years is $3.5 billion, with a median of $3.6 billion recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 58.9% in 2021, then fell 22.49% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $3.7 billion in 2021, then dropped by 15.44% to $3.1 billion in 2022, then grew by 8.98% to $3.4 billion in 2023, then increased by 15.22% to $3.9 billion in 2024, then increased by 10.75% to $4.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $4.4 billion in Q4 2025, $4.4 billion in Q3 2025, and $3.7 billion in Q2 2025.